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With some exceptions, the ﬁeld of lung cancer disease has been relatively static during the past several decades with few major practice-changing advances. In this 
issue of the journal 2, articles address the diagnosis of non-small cell lung cancer 
(NSCLC) based on small biopsies and/or cytology, an area of lung cancer diagnosis 
in which a paradigm shift has occurred for both pathologists and clinicians.1,2 This topic 
is important because the majority patients with lung cancer present with unresectable 
disease, and the diagnosis is established based on such small specimens. Moreover, with 
increasing use of minimally invasive biopsy methods, pathologists are being asked to do 
more with less tissue. 
HISTORY OF LUNG CANCER DIAGNOSIS IN SMALL BIOPSIES
 
AND CYTOLOGY
 
The World Health Organization classiﬁcations of lung tumors through the 1999 
edition3–5 did not address lung cancer diagnosis based on small biopsies and cytology, 
because these were recommendations for the histologic classiﬁcations of resection 
specimens. In the 2004 World Health Organization classiﬁcation, cytology was addressed 
for the ﬁrst time, but classiﬁcation in small biopsies was not addressed.6 Currently, no 
internationally recognized standard of criteria or terminology for the diagnosis of lung 
cancer in small biopsies is available. 
CLINICAL RELEVANCE OF HISTOLOGIC DIAGNOSIS HAS LED TO A
 
PUSH TO CLASSIFY NSCLC FURTHER
 
Historically, the most important decision for pathologists in small biopsies and 
cytology has been the crucial distinction between small cell lung cancer and NSCLC, 
because it deﬁnes patients with completely different clinical tumor behavior and man­
agement. Within NSCLC, important clinical reasons to separate squamous cell carcinoma 
from adenocarcinoma and other histologic types have not existed. 
In a literature review spanning 25 years of clinical studies evaluating chemotherapy 
in advanced NSCLC, there was some weak association between histology and therapeutic 
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outcomes,7 but none of these studies reported a formal test of 
treatment by histology interaction. Therefore, in older stud­
ies, there was no clear evidence that histology had a prog­
nostic (independent of treatment) or a predictive role (asso­
ciated with the effectiveness of a speciﬁc treatment) for 
patients with NSCLC. 
Recently, all this has been changed. Three clinical 
observations in patients with advanced lung cancer have 
provided a reason for pathologists to change their practice 
and make a better attempt to distinguish adenocarcinoma 
from squamous cell carcinoma. First, patients with advanced 
lung cancer treated with bevacizumab are at increased risk for 
life-threatening hemorrhage if they have squamous cell car­
cinoma.8 Second, patients with adenocarcinoma or NSCLC-
not otherwise speciﬁed (NSCLC-NOS; reported as large cell 
carcinoma in some of these studies) respond signiﬁcantly 
better to pemetrexed than those with squamous cell carcino­
ma.9–11 Third, EGFR mutation is strongly associated with 
adenocarcinoma histology, and patients with advanced 
NSCLC and EGFR mutation have a better outcome and 
response to tyrosine kinase inhibitors’ as a ﬁrst-line therapy, 
whereas patients without EGFR mutations seem to have a 
better outcome with chemotherapy.12 Importantly, in all these 
studies, the histologic classiﬁcation was solely based on light 
microscopy with or without mucin stains. No immunohisto­
chemistry or other special techniques were used to classify 
the tumors further. 
HISTOLOGIC HETEROGENEITY OF LUNG
 
CANCER IS AN UNDERLYING COMPLEXITY
 
One major underlying problem in addressing more 
precise classiﬁcation of small biopsies and cytology speci­
mens is the inherent histologic heterogeneity that exists in a 
subset of NSCLC.2 Roggli et al.13 addressed this in a com­
prehensive study of 100 lung cancer cases in which 39 
adenocarcinomas showed a squamous component in two 
cases (5%) and in 27 squamous cell carcinomas (excluding 
the cases with small cell carcinoma), adenocarcinoma was 
found in four cases (15%). Another difﬁculty is in tumors in 
which a solid component is sampled in small biopsy or 
cytology specimens, and the morphologic features of squa­
mous or adenocarcinoma differentiation are focal or not 
distinguishable. This has been the subject of numerous arti­
cles that demonstrate the error rate in classiﬁcation of small 
biopsies when compared with ﬁnal histologic classiﬁcation of 
the surgical specimen.14 In one such study, 10% of squamous 
cell carcinomas, 14% of adenocarcinomas, and 50% of large 
cell carcinomas were misclassiﬁed on bronchial biopsies.14 
Despite the issues of morphologic heterogeneity and 
overlapping features in tumors with solid histology, recent 
molecular studies reveal that there are clear biologic differ­
ences between lung adenocarcinoma and squamous cell car­
cinoma. In particular, gene-expression-proﬁling studies show 
distinct molecular clusters for adenocarcinoma and squamous 
cell carcinoma.15–17 In addition, EGFR and KRAS mutations 
are largely conﬁned to adenocarcinoma but are rare in squa­
mous cell carcinoma.18,19 
DO SPECIAL STUDIES MATTER? 
Based on the recent clinical observations, there is a 
growing literature regarding the pathologic characteristics 
using special techniques to distinguish adenocarcinoma from 
squamous cell carcinoma. The current articles by Loo et al. 
and Nicholson et al. are the latest additions to this literature. 
It seems from the studies by Loo et al.2 and Nicholson et al.1 
that thyroid transcription factor-1 (TTF-1) and mucin versus 
p63 stains are the best stains for detecting adenocarcinoma 
versus squamous cell carcinoma, respectively. However, 
none of the antibodies used in immunohistochemistry are 
100% speciﬁc and sensitive for this differential diagnosis. For 
example, in the study by Nicholson et al., TTF-1 was positive 
only in 13 of the 16 cases (81%), ﬁnally classiﬁed as adeno­
carcinoma including 4 of the 7 (63%) with adenocarcinoma 
morphology and 9 of the 9 (100%) initially diagnosed as 
NSCLC-NOS. One case classiﬁed as squamous cell carci­
noma also showed occasional staining for mucin. p63 is 
consistently expressed in squamous cell carcinoma, but it can 
also be seen in a subset of adenocarcinomas. As pointed out 
in both the articles, high-molecular-weight cytokeratin anti­
body 34�E12 (CK903) is highly nonspeciﬁc for distinguish­
ing adenocarcinoma and squamous cell carcinoma. Despite 
the limitations of the individual markers, evidence is emerg­
ing, as demonstrated in these two studies, that high accuracy 
can be achieved using a panel approach. A number of other 
antibodies have been reported recently including desmocol­
lin-3 and napsin.20–22 More prospective investigation is 
needed to determine whether these novel markers provide any 
added value to TTF-1, p63, and mucin stains to establish the 
optimal marker panel for the greatest diagnostic accuracy. 
Other molecular techniques, such as micro-RNA, have been 
reported to distinguish squamous cell carcinoma and adeno­
carcinoma.23 However, whether they provide any advantage 
to light microscopy and immunohistochemistry remains to be 
determined. Ultimately, a simple panel of stains should be 
used that does not exhaust tissue, which may be needed for 
predictive and prognostic molecular studies. The combination 
of these novel techniques with traditional morphology will 
hopefully lead to a more biologically precise classiﬁcation of 
NSCLC in morphologically equivocal cases. Such an ap­
proach has been quite successful in other diseases, especially 
in the diagnosis and classiﬁcation of lymphomas24 and sar­
comas.25 The prognostic and predictive impact of this ap­
proach for lung cancer will depend on analysis in prospective 
clinical studies. 
STEPWISE APPROACH TO CLASSIFICATION OF 
NSCLC-NOS 
Both articles recognize that light microscopy is sufﬁ­
cient to classify lung cancer in a subset of small biopsies or 
cytology specimens, but there remain cases that cannot be 
further classiﬁed for which they propose to use the term 
NSCLC-NOS. Using special stains, the authors identiﬁed 
characteristics that allowed them to classify most of these 
tumors further. Nicholson et al. showed that although 53% of 
the cases (17 of 32) were classiﬁed as NSCLC-NOS after the 
initial light microscopic review, after attempts to perform 
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special stains 6 of the 32 (19%) remained unclassiﬁed. 
NSCLC-NOS is a more appropriate term for these unclassi­
ﬁed cases than large cell carcinoma, as has been used in 
some, in the absence of standardized criteria and terminology 
for small biopsies or cytology.10 In some cases in which 
biopsies show NSCLC-NOS, but tumor tissue is too sparse 
for immunohistochemistry or mucin stains for more precise 
classiﬁcation or for molecular studies, if clinically indicated, 
additional biopsies may be warranted. Large cell carcinoma is 
a term that should be reserved for classiﬁcation of undiffer­
entiated NSCLC in resected specimens. 
UPCOMING INTERNATIONAL ASSOCIATION
 
FOR THE STUDY OF LUNG
 
CANCER/AMERICAN THORACIC
 
SOCIETY/EUROPEAN RESPIRATORY SOCIETY
 
INTERNATIONAL MULTIDISCIPLINARY
 
CLASSIFICATION OF LUNG
 
ADENOCARCINOMA
 
During the past 2 years, the International Association 
for the Study of Lung Cancer, American Thoracic Society, 
and European Respiratory Society have been developing a 
new International Multidisciplinary Lung Adenocarcinoma 
Classiﬁcation. The articles by Loo et al. and Nicholson et al. 
are projects that were, in part, generated in response to 
questions raised during discussions for this classiﬁcation. 
This classiﬁcation document will be published soon in the 
Journal of Thoracic Oncology. 
In this new classiﬁcation, an algorithm will be pre­
sented with recommended terminology, special stains, and 
approaches to tissue management.26 Implementation of these 
recommendations will require fundamental changes in the 
approach of obtaining small tissue and cytology samples by 
clinicians, radiologists, and surgeons. It will also require 
changes in pathologists’ approach to diagnosis including 
specimen processing and evaluation, as well as diagnostic 
terminology. 
The growing evidence for the utility of ancillary studies 
underscores the importance of obtaining sufﬁcient tissue, 
whenever clinically feasible.26 Although minimal material 
may be sufﬁcient to distinguish NSCLC from small cell lung 
cancer, additional tissue could be needed to perform immu­
nostains for subtyping of NSCLC. Together with predictive 
marker testing (often molecular tests), these new paradigms 
emphasize the need for close communication between pathol­
ogists and clinical colleagues to ensure tissue adequacy and 
optimal triage for all appropriate diagnostic studies. 
WHAT IS THE BEST APPROACH TO CLASSIFY 
NSCLC IN SMALL BIOPSIES AND CYTOLOGY? 
Of these two studies, the article by Nicholson et al. 
presents the more integrated approach to address this prob­
lem. With their approach, they include biopsy histology, 
cytology, immunohistochemistry, and EGFR mutation test­
ing.1 Cytology is a powerful modality that, in some cases, 
may allow for a more speciﬁc classiﬁcation that is not 
possible based on histology or immunohistochemistry. This 
article also points out the beneﬁts of making cell blocks from 
cytology specimens, to allow for immunohistochemistry or 
molecular studies.1 Cell blocks were made from pleural 
effusions and transbronchial needle aspirations including pro­
cedures that were blinded or guided by esophageal endo­
scopic ultrasound or endobronchial ultrasound.1 
FUTURE WORK 
With the more important role that is being assigned to 
newer diagnostic tests, a critical need exists for clinical trials 
that stratify data according to various diagnostic methods 
(i.e., light microscopic with or without mucin or immunohis­
tochemical stains), to validate which approach provides the 
best discrimination for predicting toxicity or efﬁcacy of 
chemotherapeutic regimens and other treatment modalities. 
At a minimum, clinical trials should report diagnostic criteria 
and methods used to classify tumors from enrolled patients. 
Finally, any studies that incorporate new techniques should 
compare them with currently accepted ones (i.e., TTF-1 and 
p63) to determine whether they provide any added value. 
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